Related references
Note: Only part of the references are listed.Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
Finn Edler von Eyben et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives
Philipp Backhaus et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives
Kamil Wdowiak et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role
Sophia Spatz et al.
JOURNAL OF UROLOGY (2018)
Value of 111In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up
Isabel Rauscher et al.
BJU INTERNATIONAL (2017)
Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging
James Kelly et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging
Jens Cardinale et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer
Stephanie Robu et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
Philip Cornford et al.
EUROPEAN UROLOGY (2017)
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Nicolas Mottet et al.
EUROPEAN UROLOGY (2017)
Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer
James M. Kelly et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Phase 2 Study of 99mTc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection
Karolien E. Goffin et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
A PSMA-targeted theranostic agent for photodynamic therapy
Ying Chen et al.
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY (2017)
Clinical translation of a PSMA inhibitor for 99mTc-based SPECT
Guillermina Ferro-Flores et al.
NUCLEAR MEDICINE AND BIOLOGY (2017)
99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen
Xiaoping Xu et al.
NUCLEAR MEDICINE AND BIOLOGY (2017)
PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer
Orielyz Flores et al.
THERANOSTICS (2017)
Anti-tumor effects of a recombinant anti-prostate specific membrane antigen immunotoxin against prostate cancer cells
Ping Meng et al.
BMC UROLOGY (2017)
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
Christoph A. Umbricht et al.
EJNMMI RESEARCH (2017)
Localised delivery of doxorubicin to prostate cancer cells through a PSMA-targeted hyperbranched polymer theranostic
Amanda K. Pearce et al.
BIOMATERIALS (2017)
First Experience With SPECT/CT Using a 99mTc-Labeled Inhibitor for Prostate-Specific Membrane Antigen in Patients With Biochemical Recurrence of Prostate Cancer
Julia Reinfelder et al.
CLINICAL NUCLEAR MEDICINE (2017)
Dosimetry for Lu-177-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer
Andreas Delker et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
[18F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance
Ying Chen et al.
BIOCONJUGATE CHEMISTRY (2016)
Development of 99mTc-labeled asymmetric urea derivatives that target prostate-specific membrane antigen for single-photon emission computed tomography imaging
Hiroyuki Kimura et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
64Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies
Bernhard Grubmueller et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2016)
Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer
Kambiz Rahbar et al.
CLINICAL NUCLEAR MEDICINE (2016)
PSMA Expression in Papillary Thyroid Carcinoma: Opening a New Horizon in Management of Thyroid Cancer?
Sameer Kamalakar Taywade et al.
CLINICAL NUCLEAR MEDICINE (2016)
Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands
Milan Subedi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
Frederik L. Giesel et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand
Stefano Boschi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis
Marlon Perera et al.
EUROPEAN UROLOGY (2016)
Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors
Martina Benesova et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer
Naoya Harada et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl) Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy
Ana P. Kiess et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
225Ac-PSMA-617 for PSMA-Targeted a-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen
Xinning Wang et al.
MOLECULAR CANCER THERAPEUTICS (2016)
PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer
Steven P. Rowe et al.
MOLECULAR IMAGING AND BIOLOGY (2016)
Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [177Lu]DKFZ-PSMA-617
Melanie Hohberg et al.
MOLECULAR IMAGING AND BIOLOGY (2016)
Clinical translation of 177Lu-labeled PSMA-617: Initial experience in prostate cancer patients
Tapas Das et al.
NUCLEAR MEDICINE AND BIOLOGY (2016)
Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer
Maroor Raghavan Ambikalmajan Pillai et al.
NUCLEAR MEDICINE AND BIOLOGY (2016)
Improved Synthesis and In Vitro Evaluation of an Aptamer Ribosomal Toxin Conjugate
Linsley Kelly et al.
NUCLEIC ACID THERAPEUTICS (2016)
In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer
Marta Michalska et al.
ONCOTARGET (2016)
Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
Hojjat Ahmadzadehfar et al.
ONCOTARGET (2016)
Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals
Till Wuestemann et al.
THERANOSTICS (2016)
Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
C. Parker et al.
ANNALS OF ONCOLOGY (2015)
Synthesis and evaluation of constrained phosphoramidate inhibitors of prostate-specific membrane antigen
Corinne R. Ley et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
Peter F. Mulders et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
Neeta Pandit-Taskar et al.
CLINICAL CANCER RESEARCH (2015)
Detection of Brain Metastasis With 68Ga-Labeled PSMA Ligand PET/CT A Novel Radiotracer for Imaging of Prostate Carcinoma
Partha Sarathi Chakraborty et al.
CLINICAL NUCLEAR MEDICINE (2015)
Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer
Levent Kabasakal et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Preclinical Evaluation of 86Y-Labeled Inhibitors of Prostate Specific Membrane Antigen for Dosimetry Estimates
Sangeeta Ray Banerjee et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen
Ana P. Kiess et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Biodistribution and Radiation Dosimetry for a Probe Targeting Prostate-Specific Membrane Antigen for Imaging and Therapy
Ken Herrmann et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions
Ali Afshar-Oromieh et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer
Martina Benesova et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies
Martina Weineisen et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
Markus Dietlein et al.
MOLECULAR IMAGING AND BIOLOGY (2015)
Initial Evaluation of [F-18]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer
Zsolt Szabo et al.
MOLECULAR IMAGING AND BIOLOGY (2015)
Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors
Ignace Vergote et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2015)
Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors
Neeta Pandit-Taskar et al.
EJNMMI RESEARCH (2015)
[111In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery
Margret Schottelius et al.
EJNMMI RESEARCH (2015)
Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study
Hojjat Ahmadzadehfar et al.
EJNMMI RESEARCH (2015)
The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
Ali Afshar-Oromieh et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Photoimmunotherapy Targeting Prostate-Specific Membrane Antigen: Are Antibody Fragments as Effective as Antibodies?
Rira Watanabe et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
BAY 1075553 PET-CT for Staging and Restaging Prostate Cancer Patients: Comparison with [18F] Fluorocholine PET-CT (Phase I Study)
Mohsen Beheshti et al.
MOLECULAR IMAGING AND BIOLOGY (2015)
(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors
Eleni Gourni et al.
PLOS ONE (2015)
Efficacy Studies of an Antibody-Drug Conjugate PSMA-ADC in Patient-Derived Prostate Cancer Xenografts
Vincent A. DiPippo et al.
PROSTATE (2015)
Ado-trastuzumab Emtansine: A HER2-Positive Targeted Antibody-Drug Conjugate
Patricia A. Corrigan et al.
ANNALS OF PHARMACOTHERAPY (2014)
Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers
Alla Gabriella Wernicke et al.
APMIS (2014)
Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases
Natsuko Nomura et al.
CANCER CELL INTERNATIONAL (2014)
Preclinical evaluation of BAY 1075553, a novel 18F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer
Ralf Lesche et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer
Ali Afshar-Oromieh et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
Christian M. Zechmann et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
64Cu-Labeled Inhibitors of Prostate-Specific Membrane Antigen for PET Imaging of Prostate Cancer
Sangeeta Ray Banerjee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer
Shankar Vallabhajosula et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Development of Targeted Near-Infrared Imaging Agents for Prostate Cancer
Xinning Wang et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer
Rajendra Prasad Bandari et al.
NUCLEAR MEDICINE AND BIOLOGY (2014)
The prostate-specific membrane antigen: Lessons and current clinical implications from 20 years of research
Benjamin T. Ristau et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2014)
Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA)
Florian Kampmeier et al.
EJNMMI RESEARCH (2014)
Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer
Martina Weineisen et al.
EJNMMI RESEARCH (2014)
Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer
Matthias Eder et al.
PHARMACEUTICALS (2014)
Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A-DTPA-DUPA-Pep
Benjamin Baur et al.
PHARMACEUTICALS (2014)
Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography
Alejandro Sanchez-Crespo
APPLIED RADIATION AND ISOTOPES (2013)
Synthesis and SAR of 99mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates
Genliang Lu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
A. Afshar-Oromieh et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Effect of Chelators on the Pharmacokinetics of 99mTc-Labeled Imaging Agents for the Prostate-Specific Membrane Antigen (PSMA)
Sangeeta Ray Banerjee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Preparation of Asymmetric Urea Derivatives that Target Prostate-Specific Membrane Antigen for SPECT Imaging
Naoya Harada et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer
John A. Barrett et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer
Shawn M. Hillier et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
PSMA-targeted SPECT agents: Mode of binding effect on in vitro performance
Jessie R. Nedrow-Byers et al.
PROSTATE (2013)
An Anti-PSMA Bivalent Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Imaging and Therapy
Fayun Zhang et al.
ADVANCED HEALTHCARE MATERIALS (2013)
Combination of the PI3K Inhibitor ZSTK474 with a PSMA-Targeted Immunotoxin Accelerates Apoptosis and Regression of Prostate Cancer
Daniele Baiz et al.
NEOPLASIA (2013)
68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging
Matthias Eder et al.
BIOCONJUGATE CHEMISTRY (2012)
DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time
Lindsey Chudley et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
[68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH
A. Afshar-Oromieh et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Advances in Immuno-Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology
Scott M. Knowles et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity
Michael C. Haffner et al.
MODERN PATHOLOGY (2012)
A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent
Jessie R. Nedrow-Byers et al.
PROSTATE (2012)
A dimerized urea-based inhibitor of the prostate-specific membrane antigen for Ga-68-PET imaging of prostate cancer
Martin Schaefer et al.
EJNMMI RESEARCH (2012)
Prostate-Specific Membrane Antigen as a Potential Novel Vascular Target for Treatment of Glioblastoma Multiforme
A. Gabriella Wernicke et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2011)
Photodynamic Therapy of Cancer: An Update
Patrizia Agostinis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer
Ying Chen et al.
CLINICAL CANCER RESEARCH (2011)
Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature
Mary K. Samplaski et al.
MODERN PATHOLOGY (2011)
A targeted low molecular weight near-infrared fluorescent probe for prostate cancer
Tiancheng Liu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies
Haofan Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption
Tiancheng Liu et al.
CANCER LETTERS (2010)
Preclinical Evaluation of a Recombinant Anti-Prostate Specific Membrane Antigen Single-Chain Immunotoxin Against Prostate Cancer
Philipp Wolf et al.
JOURNAL OF IMMUNOTHERAPY (2010)
68Ga-Labeled Inhibitors of Prostate-Specific Membrane Antigen (PSMA) for Imaging Prostate Cancer
Sangeeta Ray Banerjee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer
Shawn M. Hillier et al.
CANCER RESEARCH (2009)
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers
Michael C. Haffner et al.
HUMAN PATHOLOGY (2009)
A Series of Halogenated Heterodimeric Inhibitors of Prostate Specific Membrane Antigen (PSMA) as Radiolabeled Probes for Targeting Prostate Cancer
K. P. Maresca et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Assessment of an 18F-Labeled Phosphoramidate Peptidomimetic as a New Prostate-Specific Membrane Antigen-Targeted Imaging Agent for Prostate Cancer
Suzanne E. Lapi et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted 99mTc-Radioimaging Agents
Sumith A. Kularatne et al.
MOLECULAR PHARMACEUTICS (2009)
In Vitro Targeted Photodynamic Therapy With a Pyropheophorbide-a Conjugated Inhibitor of Prostate-Specific Membrane Antigen
Tiancheng Liu et al.
PROSTATE (2009)
N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC:: A new imaging probe for prostate cancer
Ronnie C. Mease et al.
CLINICAL CANCER RESEARCH (2008)
Synthesis and evaluation of technetium-99m-and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA)
Sangeeta R. Banerjee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer
Ying Chen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Anti-PSMA immunotoxin as novel treatment for prostate cancer?: High and specific antitumor activity on human prostate xenograft tumors in SCID mice
Philipp Wolf et al.
PROSTATE (2008)
Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis
Petra Mlcochova et al.
FEBS JOURNAL (2007)
Production of multimeric prostate-specific membrane antigen small-molecule radiotracers using a solid-phase 99mTc preloading strategy
Preeti Misra et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms
Angelo Baccala et al.
UROLOGY (2007)
Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II
Cyril Barinka et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique
P. Mhawech-Fauceglia et al.
HISTOPATHOLOGY (2007)
Expression of glutamate carboxypeptidase II in human brain
P. Sacha et al.
NEUROSCIENCE (2007)
A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells
P. Wolf et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Association of prostate-specific membrane antigen with caveolin-1 and its caveolae-dependent internalization in microvascular endothelial cells: Implications for targeting to tumor vasculature
Gopalakrishnapillai Anilkumar et al.
MICROVASCULAR RESEARCH (2006)
Aptamer:toxin conjugates that specifically target prostate tumor cells
Ted C. Chu et al.
CANCER RESEARCH (2006)
Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen
DS Ma et al.
CLINICAL CANCER RESEARCH (2006)
Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer
JR Mesters et al.
EMBO JOURNAL (2006)
Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy
Sarva Jayaprakash et al.
CHEMMEDCHEM (2006)
NAAG peptidase inhibitors and their potential for diagnosis and therapy
J Zhou et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
NH Bander et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Radiolabeled small-molecule ligands for prostate-specific membrane antigen:: In vivo imaging in experimental models of prostate cancer
CA Foss et al.
CLINICAL CANCER RESEARCH (2005)
Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase
MI Davis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Radiohalogens for imaging and therapy
MJ Adam et al.
CHEMICAL SOCIETY REVIEWS (2005)
Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene
DS O'Keefe et al.
PROSTATE (2004)
Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and plouse prostate-specific membrane antigen
XM Huang et al.
PROSTATE (2004)
Nature of urea-fluoride interaction:: Incipient and definitive proton transfer
M Boiocchi et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2004)
A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer
MD Henry et al.
CANCER RESEARCH (2004)
Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies
PJ Russell et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Anti-tumor effects of toxins targeted to the prostate specific membrane antigen
G Fracasso et al.
PROSTATE (2002)
11C-MCG: Synthesis, Uptake Selectivity, and Primate PET of a Probe for Glutamate Carboxypeptidase II (NAALADase)
Martin G. Pomper et al.
MOLECULAR IMAGING (2002)
Glutamate as a neurotransmitter in the brain: Review of physiology and pathology
BS Meldrum
JOURNAL OF NUTRITION (2000)
Share Paper
